Monte Rosa Therapeutics (GLUE) Free Cash Flow (2020 - 2026)

Monte Rosa Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$40.1 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 12.43% year-over-year to -$40.1 million in Q1 2026; TTM through Mar 2026 was -$17.3 million, a 148.89% decrease from a year earlier, with the FY2025 full-year figure at -$22.9 million, down 154.71% from the prior year.
• Free Cash Flow advanced to -$40.1 million in Q1 2026 per GLUE's latest filing, from -$42.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $132.7 million in Q4 2024 and bottomed at -$45.8 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$30.2 million (2024), against an average of -$11.1 million.
• Across the five-year window, Free Cash Flow plunged 148.64% in 2022 and soared 1018.41% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$32.1 million in 2022, then soared by 136.93% to $11.9 million in 2023, then surged by 1018.41% to $132.7 million in 2024, then sank by 132.2% to -$42.7 million in 2025, then grew by 6.13% to -$40.1 million in 2026.
• Per Business Quant, the three latest GLUE Free Cash Flow figures stand at -$40.1 million (Q1 2026), -$42.7 million (Q4 2025), and $103.3 million (Q3 2025).